Safety and Effectiveness of a Biosimilar Recombinant Human Growth Hormone in Children Requiring Growth Hormone Treatment: Analysis of Final Data from PATRO Children, an International, Post-Marketing Surveillance Study [PDF]
Sandro Loche,1 Shankar Kanumakala,2 Philippe Backeljauw,3 Karl Otfried Schwab,4 Alfonso M Lechuga-Sancho,5– 7 Altaher Esmael,8 Dragan Urosevic,9 Anca Boldea,8 Markus Zabransky8 1Endocrinologia Pediatra e Centro, Screening Neonatale, Ospedale Pediatrico ...
Loche S +8 more
doaj +5 more sources
Safety and effectiveness of Omnitrope® (somatropin) in PATRO Children: a multi-center, post-marketing surveillance study comparison of US and international cohort data. [PDF]
There are known geographical differences in growth hormone deficiency (GHD) patient populations and treatment practices. Here, we present a comparison of safety and effectiveness data from patients treated with recombinant human growth hormone (rhGH) in ...
Backeljauw P +9 more
europepmc +2 more sources
Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study. [PDF]
Background: PATRO Children is an ongoing observational, longitudinal, non-interventional, global post-marketing surveillance study, which is investigating the long-term safety and effectiveness of Omnitrope®, a somatropin biosimilar to Genotropin®, in ...
Iughetti L +17 more
europepmc +2 more sources
Long-term safety and efficacy of Omnitrope® in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study. [PDF]
To report the long-term effectiveness and safety of the recombinant human growth hormone Omnitrope(®), a somatropin biosimilar to Genotropin(®), in Italian patients with growth hormone deficiency (GHD) enrolled in the PATRO Adults ...
Ferone D +11 more
europepmc +3 more sources
Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone deficiency: results from an international, post-marketing surveillance study (PATRO Adults). [PDF]
To evaluate safety and effectiveness of biosimilar recombinant human growth hormone (rhGH; Omnitrope®) in adults with growth hormone deficiency (GHD), using data from the PATRO Adults study.PATRO Adults was a post-marketing surveillance study conducted ...
Höybye C +8 more
europepmc +2 more sources
A follow-up study to monitor adult height among Spanish children with growth hormone deficiency who received biosimilar human recombinant growth hormone (Omnitrope®) during a phase III clinical trial. [PDF]
An initial Phase III clinical trial has evaluated the efficacy and safety of biosimilar recombinant human growth hormone (rhGH; Omnitrope(®), Sandoz) in Spanish children with growth hormone deficiency (GHD).
Borrás Pérez V +13 more
europepmc +2 more sources
Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data. [PDF]
In 2006, the European Medicines Agency (EMA) approved Omnitrope(®) as a biosimilar recombinant human growth hormone (rhGH), on the basis of comparable quality, safety, and efficacy to the reference medicine (Genotropin(®), Pfizer).
López-Siguero JP +5 more
europepmc +2 more sources
Safety and Effectiveness of a Biosimilar Recombinant Growth Hormone in Adults with Growth Hormone Deficiency: Analysis of Final Data from PATRO Adults, an International Post-Marketing Surveillance Study [PDF]
Paolo Beck-Peccoz,1 Charlotte Höybye,2 Suat Simsek,3 Günter Stalla,4 Robert D Murray,5 Altaher Esmael,6 Dragan Urosevic,7 Anca Boldea,6 Markus Zabransky6 1Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Cà Granda Ospedale Maggiore ...
Beck-Peccoz P +8 more
doaj +2 more sources
Ten years of clinical experience with biosimilar human growth hormone: a review of safety data [PDF]
Maria Victoria Borrás Pérez,1 Berit Kriström,2 Tomasz Romer,3 Mieczyslaw Walczak,4 Nadja Höbel,5 Markus Zabransky5 1Hospital General de Granollers, Granollers, Barcelona, Spain; 2Department of Clinical Sciences, Pediatrics, Ume ...
Borrás Pérez MV +5 more
doaj +2 more sources
Safety and effectiveness of a somatropin biosimilar in children requiring growth hormone treatment: second analysis of the PATRO Children study Italian cohort [PDF]
Purpose: To investigate the long-term safety (primary endpoint) and effectiveness (secondary endpoint) of the somatropin biosimilar Omnitrope®. Methods: PATRO Children is an ongoing, multicenter, observational, post-marketing surveillance study. Children
Greggio N. A. +57 more
core +1 more source

